Trinity is expanding its artificial intelligence capabilities for pharmaceutical commercialization through the acquisition of Verix, bringing the company's Tovana platform into its TrinityEDGE ecosystem. The deal adds AI-powered next-best-action recommendations, dynamic targeting and omnichannel orchestration to Trinity's portfolio, aiming to help pharmaceutical and biotechnology companies translate commercial intelligence into coordinated customer engagement. Financial terms were not disclosed, and the companies expect their first joint offerings to reach clients in the first half of 2027.

Trinity’s acquisition of Verix gives the life sciences commercialization company a technology layer designed to connect data analysis with day-to-day decisions made by pharmaceutical sales and marketing teams. The combined platform will bring customer intelligence, targeting recommendations and coordinated engagement into a more integrated commercial workflow.

Verix developed Tovana, a patented AI-powered commercial intelligence platform that processes prescription, claims, clinical and engagement data. It uses those inputs to generate next-best-action recommendations, adjust customer targeting and coordinate interactions across field sales and digital channels. Trinity says the technology has been deployed in pharmaceutical and biotechnology organizations since 2007.

The acquisition adds execution capabilities to TrinityEDGE, Trinity’s commercialization platform. Verix’s full team will join Trinity, while Verix CEO Doron Aspitz will join the leadership team and continue guiding Tovana’s product roadmap. The companies did not disclose the financial terms.

Closing the gap between AI insights and commercial action

The deal addresses a persistent challenge in pharmaceutical marketing: organizations can generate extensive customer and market intelligence without consistently translating it into timely action.

Commercial teams often work with separate analytics, customer engagement and sales systems. Targeting decisions can become outdated between planning cycles, while field representatives may disregard AI recommendations if the rationale is unclear or the advice does not fit their existing workflows.

Tovana is designed to address that disconnect by continuously updating targeting and engagement recommendations as new data becomes available. Its recommendations can inform brand strategy, field interactions and digital outreach rather than leaving each channel to operate from separate plans.

Trinity's own 2025 benchmarks illustrate the implementation problem. The company reported that all surveyed commercial and medical IT organizations had adopted generative AI in some capacity, but their average confidence in innovation was just 3 out of 5. In a separate survey of new product planning and commercial strategy leaders, only 10% reported having a clear AI strategy that they were scaling across workflows. These are company-reported findings, not an industry-wide census.

The broader pattern is consistent with research from McKinsey & Company. Its 2024 survey of more than 100 pharmaceutical and medical technology leaders found that all respondents had experimented with generative AI, but only 5% said they had achieved a competitive differentiator producing consistent, significant financial value.

From analytics to an integrated execution layer

Tovana's integration is intended to reduce the distance between commercial planning and execution. Trinity says its existing pharmaceutical data foundation, automated pipelines and prebuilt models can help customers deploy targeting and engagement capabilities within a single planning cycle.

The company also cites customer-reported outcomes from existing deployments. One large US pharmaceutical oncology division increased leading commercial key performance indicators, including new prescriptions, by 15% to 25%. A rare oncology therapy team reported a twelvefold improvement in field-facing net promoter score. These figures are supplied by Trinity and Verix; independently verified methodologies and detailed customer-level data were not provided in the announcement.

The integration will extend to FieldAdvisor, Trinity's field-facing workflow, where recommendations are intended to include explanations and supporting context. That detail matters in pharmaceutical sales, where representatives must make informed decisions within complex therapeutic markets and operate under strict compliance requirements.

Tovana's capabilities will be progressively integrated into TrinityEDGE's single sign-on environment over the coming months. The first joint offerings are expected in the first half of 2027, with CustomerEDGE execution among the areas expected to benefit.

What the acquisition means for pharmaceutical marketers

For enterprise marketing teams, the strategic proposition is consolidation: connect market research, commercial analytics, targeting and customer engagement through one provider instead of coordinating multiple vendors and integrations.

Trinity brings commercialization strategy, launch planning, market access and competitive benchmarking. Verix adds an established AI-based execution product. Together, those capabilities could help teams update engagement plans more frequently and align field representatives with digital marketing activity.

The acquisition does not, however, establish that the combined platform will outperform competing systems. Trinity has not disclosed pricing, detailed integration milestones, independent comparative benchmarks or evidence that the reported customer results will generalize across therapeutic categories.

Pharmaceutical buyers will also need to assess data quality, explainability, interoperability, privacy controls and governance before expanding AI-driven commercial decisions. In a regulated industry, recommendations must be useful without compromising approved messaging, customer-data safeguards or internal review processes.

The key test will be whether Trinity can integrate Tovana into its broader platform without disrupting existing customers—and demonstrate measurable improvements beyond those reported in selected deployments. The acquisition positions Trinity to compete more directly in AI-enabled pharmaceutical commercial execution, but the combined product's broader value will depend on implementation, adoption and independently measurable outcomes.

Market Landscape

The pharmaceutical commercial technology market is moving beyond standalone analytics toward systems that recommend and coordinate actions across sales representatives, digital channels and brand teams. The opportunity is not simply to add generative AI to existing software; it is to connect fragmented data and decision-making processes.

McKinsey estimated that generative AI could create $18 billion to $30 billion in annual economic value across commercial functions in pharmaceutical and medical technology companies. That figure represents a modeled opportunity, not realized savings or revenue.

Trinity's approach competes with several established technology categories:

• Enterprise CRM and life sciences platforms: Salesforce offers life sciences CRM and customer engagement capabilities, while other enterprise platforms support commercial workflows and customer data management.

• Marketing automation and customer engagement: Platforms from Adobe and other vendors coordinate audience engagement, campaign execution and personalization, although pharmaceutical-specific workflows and data requirements vary.

• Commercial analytics and decision intelligence: Specialized vendors focus on prescription data, customer segmentation, forecasting and next-best-action recommendations. Tovana's differentiation is its pharmaceutical focus and intended connection between analytics and execution.

These offerings are not interchangeable, and their capabilities overlap to different degrees. Trinity's competitive opportunity lies in combining its commercialization expertise with Verix's established decisioning technology, rather than competing solely on general-purpose AI models.

Strategic Outlook

The next phase of enterprise AI adoption will depend on whether vendors can move from producing insights to embedding recommendations in workflows that employees already use. Gartner predicted in January 2026 that 60% of brands would use agentic AI to facilitate streamlined one-to-one interactions by 2028, highlighting the broader shift toward coordinated, AI-supported engagement.

Trinity's acquisition fits that direction, although Tovana's announced capabilities should not automatically be classified as agentic AI. Its described functions center on next-best-action, targeting and orchestration; the announcement does not establish the level of autonomous decision-making or execution.

For pharmaceutical marketing leaders, the near-term priorities are practical: verify integration with existing CRM and data infrastructure, establish clear human oversight, measure adoption by field teams, and compare incremental commercial outcomes against a defined baseline. Trinity's first joint offerings, expected in the first half of 2027, should provide a clearer indication of how effectively the acquisition translates into a unified commercial platform.

Top Insights

• Trinity acquires Verix: The deal adds Tovana's AI-powered next-best-action and omnichannel orchestration capabilities to TrinityEDGE, targeting pharmaceutical and biotechnology commercial teams.

• AI execution becomes the focus: Trinity is addressing the gap between analytics and action, a challenge for marketing leaders seeking measurable returns from existing AI investments.

• Commercial results need validation: Trinity reports prescription KPI improvements of 15% to 25% in one oncology division, but independent verification and detailed measurement methods remain undisclosed.

• Integration is the next milestone: Tovana capabilities will progressively enter TrinityEDGE, with the first joint offerings planned for the first half of 2027.

• Enterprise buyers retain due diligence responsibilities: Pharma marketing teams must evaluate explainability, data governance, workflow adoption and measurable ROI before expanding AI-driven commercial engagement.

Get in touch with our MarTech Experts.